These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
4. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. Han Y; Xie Z; Zang Y; Zhang S; Gu D; Zhou M; Gevaert O; Wei J; Li C; Chen H; Du J; Liu Z; Dong D; Tian J; Zhou D J Neurooncol; 2018 Nov; 140(2):297-306. PubMed ID: 30097822 [TBL] [Abstract][Full Text] [Related]
5. Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence. Akkus Z; Ali I; Sedlář J; Agrawal JP; Parney IF; Giannini C; Erickson BJ J Digit Imaging; 2017 Aug; 30(4):469-476. PubMed ID: 28600641 [TBL] [Abstract][Full Text] [Related]
6. MRI Features Can Predict 1p/19q Status in Intracranial Gliomas. Lasocki A; Gaillard F; Gorelik A; Gonzales M AJNR Am J Neuroradiol; 2018 Apr; 39(4):687-692. PubMed ID: 29519793 [TBL] [Abstract][Full Text] [Related]
7. Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. van der Voort SR; Incekara F; Wijnenga MMJ; Kapas G; Gardeniers M; Schouten JW; Starmans MPA; Nandoe Tewarie R; Lycklama GJ; French PJ; Dubbink HJ; van den Bent MJ; Vincent AJPE; Niessen WJ; Klein S; Smits M Clin Cancer Res; 2019 Dec; 25(24):7455-7462. PubMed ID: 31548344 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy. Pandith AA; Zahoor W; Manzoor U; Nisar S; Guru FR; Naikoo NA; Aein QU; Baba SM; Bhat AR; Ganai F; Shah P Cancer Genet; 2023 Nov; 278-279():55-61. PubMed ID: 37625215 [TBL] [Abstract][Full Text] [Related]
10. Static and dynamic Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400 [TBL] [Abstract][Full Text] [Related]
11. Prediction of Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763 [TBL] [Abstract][Full Text] [Related]
12. Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system. Ręcławowicz D; Stempniewicz M; Biernat W; Limon J; Słoniewski P Folia Neuropathol; 2013; 51(1):26-32. PubMed ID: 23553134 [TBL] [Abstract][Full Text] [Related]
13. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Yao J; Hagiwara A; Raymond C; Shabani S; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM Sci Rep; 2020 Jul; 10(1):11922. PubMed ID: 32681084 [TBL] [Abstract][Full Text] [Related]
14. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
15. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
16. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974 [TBL] [Abstract][Full Text] [Related]
17. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142 [TBL] [Abstract][Full Text] [Related]
18. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924 [TBL] [Abstract][Full Text] [Related]
19. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986 [TBL] [Abstract][Full Text] [Related]
20. Predicting 1p/19q co-deletion status from magnetic resonance imaging using deep learning in adult-type diffuse lower-grade gliomas: a discovery and validation study. Yan J; Zhang S; Sun Q; Wang W; Duan W; Wang L; Ding T; Pei D; Sun C; Wang W; Liu Z; Hong X; Wang X; Guo Y; Li W; Cheng J; Liu X; Li ZC; Zhang Z Lab Invest; 2022 Feb; 102(2):154-159. PubMed ID: 34782727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]